Empowering Healthcare Innovation: Keiretsu Forum to Feature Achievements of PhotoniCare at the 2024 Innovation Funders Showcase

Philadelphia, PA – [April 16, 2024] – In anticipation of the Innovation Funders Showcase at the Angel Capital Association's 2024 Summit, Keiretsu Forum Mid-Atlantic, South-East, and Texas is proud to announce a sponsored portfolio company that exemplifies the pinnacle of healthcare innovation. PhotoniCare has set a commendable milestone by enriching the lives of more than 20,000 patients, imaging their 20,000th patient in Q1 through its pioneering light-based technologies designed to revolutionize patient care.

Steadfast in its quarterly growth and the increased recognition from insurance companies, PhotoniCare has validated its promise to enhance healthcare delivery. The OtoSight Middle Ear Scope reflects PhotoniCare’s commitment to innovation and excellence, remaining at the forefront for healthcare providers in diagnosing and managing otitis media—a prevalent condition among children and adults globally.

PhotoniCare’s pursuit of excellence is further demonstrated by its latest achievement: the onboarding of its 7th facility in an 800-patient, outcomes-focused randomized controlled trial (RCT). This serves as a testament to the company’s allegiance to evidence-based medicine and verifiable patient outcomes.

Investment Opportunity with PhotoniCare

Having navigated Keiretsu Forum’s comprehensive Due Diligence process successfully, PhotoniCare conveys a strong message of transparency and rigor—offering prospective investors a detailed report and investment portfolio for consideration.

The Angel Capital Association's 2024 Summit, set to unfold in Columbus, Ohio, on May 13-15, 2024, promises to be a convergence of innovation and investor acumen. PhotoniCare joins a curated list of companies demonstrating the potential to reshape industries with their technologies and philosophies.

For more information about PhotoniCare and its participation in the ACA Summit's Innovation Funders Showcase, please contact Cindi Sutera at cindis@amscommunications.net or call 610-613-2773.

PhotoniCare logo

About PhotoniCare

Founded in 2013, PhotoniCare’s mission is to improve clinical outcomes and serve the unmet patient and provider needs by translating novel light-based technologies into objective medical practice. The FDA-cleared OtoSightTM Middle Ear Scope was developed by PhotoniCare to eliminate subjectivity by providing users with a non-invasive and comprehensive assessment of middle ear fluid, even in the presence of earwax. PhotoniCare has developed a patented imaging platform that provides growth opportunities beyond otology.

PhotoniCare has been recognized by numerous organizations, winning the 2021 Northwest Arkansas Tech Summit Pitch Competition, the 2018 MedTech Innovator Execution Award, and the 2018 AdvaMed Accel Virginia Shimer Rybski Memorial Award. The company was also a member of the 2016 Dreamit Ventures accelerator program and took first place at the 7th Annual Insight Product Development 2019 HealthTECH Startup Competition. PhotoniCare has received more than $6 million in support from the National Institutes of Health, most recently a Phase SBIR II award for work in artificial intelligence. In 2015, PhotoniCare was the winner of a grant from the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), an FDA-funded consortium led by Children’s National Hospital.

About Keiretsu Forum Mid-Atlantic, South-East and Texas

Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 34 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

---